Article
Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIH-EXAMINER as a potential clinical trial endpoint.
Alzheimer's & dementia : the journal of the Alzheimer's Association - 1 Jan 2020
Staffaroni Adam M, Bajorek Lynn, Casaletto Kaitlin B, Cobigo Yann, Goh Sheng-Yang M, Wolf Amy, Heuer Hilary W, Elahi Fanny M, Ljubenkov Peter A, Dever Reilly, Kornak John, Appleby Brian, Bove Jessica, Bordelon Yvette, Brannelly Patrick, Brushaber Danielle, Caso Christina, Coppola Giovanni, Dheel Christina, Dickerson Bradford C, Dickinson Susan, Dominguez Sophia, Domoto-Reilly Kimiko, Faber Kelly, Ferrall Jessica, Fields Julie A, Fishman Ann, Fong Jamie, Foroud Tatiana, Forsberg Leah K, Gavrilova Ralitza, Gearhart Debra, Ghazanfari Behnaz, Ghoshal Nupur, Goldman Jill, Graff-Radford Jonathan, Graff-Radford Neill, Grant Ian, Grossman Murray, Haley Dana, Hsiung Ging-Yuek, Huey Edward D, Irwin David J, Jones David T, Jones Lynne, Kantarci Kejal, Karydas Anna, Kaufer Daniel I, Kerwin Diana R, Knopman David S, Kraft Ruth, Kremers Walter K, Kukull Walter A, Litvan Irene, Lucente Diane, Lungu Codrin, Mackenzie Ian R, Maldonado Miranda, Manoochehri Masood, McGinnis Scott M, McKinley Emily, Mendez Mario F, Miller Bruce L, Multani Namita, Onyike Chiadi, Padmanabhan Jaya, Pantelyat Alex, Pearlman Rodney, Petrucelli Len, Potter Madeline, Rademakers Rosa, Ramos Eliana Marisa, Rankin Katherine P, Rascovsky Katya, Roberson Erik D, Rogalski Emily, Sengdy Pheth, Shaw Leslie M, Syrjanen Jeremy, Tartaglia M Carmela, Tatton Nadine, Taylor Joanne, Toga Arthur, Trojanowski John Q, Weintraub Sandra, Wang Ping, Wong Bonnie, Wszolek Zbigniew, Boxer Adam L, Boeve Brad F, Kramer Joel H, Rosen Howard J
Abstract excerpt
INTRODUCTION: Identifying clinical measures that track disease in the earliest stages of frontotemporal lobar degeneration (FTLD) is important for clinical trials. Familial FTLD provides a unique paradigm to study early FTLD. Executive dysfunction is a clinically relevant hallmark of FTLD and may be a marker of disease progression. METHODS: Ninety-three mutation carriers with no symptoms or minimal/questionable...